Taztia XT

This page contains recent news articles, when available, and an overview of Taztia XT but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

SHAREHOLDER VOTE ON SALE SCHEDULED FOR JUNE 28  -  May 19, 2006
...recall or reduction in manufacturing or distribution of four key Andrx products -- heart drugs Cartia XT and Taztia XT, cholesterol drug Altoprev or ... Pay-Per-View - South Florida Sun - Sentinel - ProQuest Archiver

Company Profile Report  -  Sep 30, 2006
Andrx Pharmaceuticals Cartia XT (Diltiazem HCl Extended-Release); Andrx Pharmaceuticals Taztia XT (Diltiazem HCl Extended Release). Heart Failure (HF) ... $50.00 - Revere Reports - Revere

Competitors by Product Report  -  Aug 2, 2008
Andrx Pharmaceuticals Taztia XT (Diltiazem HCl Extended Release); Dilacor XR (Diltiazem HCl); Diltiazem HCl; Nifedipine ER; Verapamil HCl/HCl SR ... $75.00 - Revere Reports - Revere

Competitors by Product Report  -  Aug 2, 2008
Andrx Pharmaceuticals Taztia XT (Diltiazem HCl Extended Release); Dilacor XR (Diltiazem HCl); Diltiazem HCl; Nifedipine ER; Verapamil HCl/HCl SR ... $75.00 - Revere - Alacra Store

Generics makers keep new products coming.(RX/GENERICS)(Statistical …  -  Sep 17, 2007
Fluconazole $54594508.70 Watson Labs Taztia XT $53746455.48 Watson Labs Trivora-28 $53639460.63 Ranbaxy Minocycline HCl $53560815.06 Sandoz Lisinopril ... Free with registration - Chain Drug Review - AccessMyLibrary.com

Drug/Medical Device  -  Sep 30, 2006
Andrx Pharmaceuticals Taztia XT (Diltiazem HCl Extended Release), Chronic Stable Angina, Hypertension, Tentatively Approved. Heart Failure (HF) ... $70.00 - Revere Reports - Revere

Kansas Regulations - 129-5-1. Prior authorization.  -  Nov 3, 2005
...with the following brand names: (i) Cardizen SR® (ii) Cardizem CD® (iii) Cartia XT® (iv) Dilacor XR® (v) Taztia XT® and (vi) Cardizem LA® (B) verapamil ... Pay-Per-View - Kansas Regulations - Loislaw

Watson Pharmaceuticals, Inc./ Andrx Corporation Merger & …  -  Mar 13, 2006
The current market product includes a [INAUDIBLE] process as Cartia XL, Taztia XT, Diltia XT, Buformin ER. Its pipeline product, including generic Toprol-XL ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com

Global top 200 brand-name drugs ranked by retail sales in dollars and...  -  Feb 21, 2005
Necon 1/35 77558 -10.3 176 NuvaRing 75545 87.5 177 Elocon 75245 2.5 178 Taztia XT 71957 63.5 179 Climara 70197 2.5 180 Digitek 68624 -11.1 181 Estrostep ... $20.00 - Drug Topics - Alacra Store

Top 200 brand name drugs by units in 2006.(COMMUNITY PRACTICE)( …  -  Mar 5, 2007
1246 -2.1 190 AndroGel 1246 4.8 191 Necon 0.5/35E 1243 -6.0 192 Jantoven 1235 53.8 193 Methylin 1229 4.4 194 Taztia XT 1223 -2.3 195 Uroxatral 1217 32.1 ... $4.95 - Drug Topics - ECNext

Competitors by Product Report  -  Dec 16, 2006
Andrx Pharmaceuticals Taztia XT (Diltiazem HCl Extended Release); Dilacor XR (Diltiazem HCl); Diltiazem HCl; Nifedipine ER; Verapamil HCl/HCl SR ... $75.00 - Revere Reports - Revere

Competitors by Product Report  -  Sep 30, 2006
Andrx Pharmaceuticals Cartia XT (Diltiazem HCl Extended-Release); Andrx Pharmaceuticals Taztia XT (Diltiazem HCl Extended Release) ... $75.00 - Revere Reports - Revere

Top 200 brand-name drugs by units in 2005.(rankings )  -  Mar 20, 2006
1263 1.6 197 Relpax 1260 50.1 198 Cenestin 1258 -7.1 199 Aldara 1253 3.1 200 Taztia XT 1252 -7.6 All others 274162 -21.8% Source: Verispan, VONA. Free with registration - Drug Topics - AccessMyLibrary.com

Andrx Corporation Reports Financial Results for 2006 Second Quarter.  -  Aug 8, 2006
In our generic products business, although revenues continue to be affected by no launches, Cartia XT(R) and Taztia XT(R) have not been impacted by ... $4.95 - Business Wire - ECNext

Finance; Andrx reports distributed products revenue increased 11.5%  -  Sep 5, 2006
In our generic products business, although revenues continue to be affected by no launches, Cartia XT and Taztia XT have not been impacted by additional ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones

Article: Generic Tiazac gets OK(GENERIC DRUGS)(Brief article) - Chain...  -  Sep 25, 2006
Andrx, in discussions with the FDA over dosage strengths of its Taztia XT product, expects a 2002 launch ... Computer Shopper. Article: The Genius of Edison ... Pay-Per-View - Chain Drug Review - HighBeam Research





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines


The Cancer News Network


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.



COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy